Ryan Taber – Nectero Therapeutics

Data Presented on Two-Year Proximal Neck Dynamics From First-in-Human Study of Abdominal Aortic Aneurysm Treatment

June 25, 2026 / July 1, 2026 by Ryan Taber

Tempe, AZ – June 25, 2026 – Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational Nectero EAST® System. The study met safety endpoints, and AAA growth rates were significantly lower than expected through two years post-treatment. At the […]

Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms

April 23, 2026 by Ryan Taber

London, England – April 23, 2026 – Nectero Therapeutics, a clinical-stage biotechnology company developing therapies for aneurysmal disease, released two-year outcomes data today from the company’s first-in-human (FIH) trial of their investigational Nectero EAST® System. The results were presented at Charing Cross 2026 by Dr. Andrew Holden during a session on Abdominal Aortic Aneurysm (AAA) […]